fosaprepitant 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
neurokinin NK1 (substance P) receptor antagonist 4470 172673-20-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ivemend
  • fosaprepitant
  • fosaprepitant dimeglumine
  • fosaprepitant meglumine
a pro-drug form of aprepitant
  • Molecular weight: 614.41
  • Formula: C23H22F7N4O6P
  • CLOGP: 2.19
  • LIPINSKI: 1
  • HAC: 10
  • HDO: 3
  • TPSA: 123.93
  • ALOGS: -4.99
  • ROTB: 9
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution) 0.07 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 18.60 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.20 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 100 mg/mL Bocci G, Oprea TI, Benet LZ

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 0.231 Moderate 0.76
caco2-efflux Caco-2 efflux ratio (BA/AB) 11.776 Moderate 0.76
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.387 10^-6 cm/s Moderate 0.76
dh-clint Dog hepatocyte intrinsic clearance 6.081 uL/min/10^6 cells Moderate 0.76
dppb Dog plasma protein binding (% unbound) 4 % Moderate 0.76
fcs-ppb Fetal calf serum protein binding (% unbound) 3.840 % Moderate 0.76
herg hERG pIC50 4.811 pIC50 Moderate 0.76
hh-clint Human hepatocyte intrinsic clearance 2.985 uL/min/10^6 cells Moderate 0.76
hlm-clint Human liver microsomal intrinsic clearance 3.062 uL/min/mg protein Moderate 0.76
hppb Human plasma protein binding (% unbound) 2.550 % Moderate 0.76
kinase-safety-class ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAPK7,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CG,PRKDC,TEK,TGFBR1,ZAP70 23
kinase-selectivity-class AXL,EPHB4,GRK2,MAP2K6,MAPK7,TEK 6
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 1.358 Moderate 0.76
mh-clint Mouse hepatocyte intrinsic clearance 13.335 Moderate 0.76
mppb Mouse plasma protein binding (% unbound) 3.340 Moderate 0.76
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.047 Moderate 0.76
pfas-class PFAS structural alert (1 = True, 0 = False) 1
pppb Pig plasma protein binding (% unbound) 3.230 % Moderate 0.76
rh-clint Rat hepatocyte intrinsic clearance 6.577 uL/min/10^6 cells Moderate 0.76
rh-fuinc Rat hepatocyte fraction unbound in incubation 57.030 % Moderate 0.76
rppb Rat plasma protein binding (% unbound) 3.010 % Moderate 0.76
solubility-dd Solubility at pH 7.4 in DMSO 977.237 uM Moderate 0.76

Approvals:

DateAgencyCompanyOrphan
March 27, 2003 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 374.22 18.88 491 59355 157858 90410743
Drug ineffective 315.89 18.88 272 59574 1384026 89184575
Sleep disorder due to general medical condition, insomnia type 270.35 18.88 377 59469 128317 90440284
Ill-defined disorder 226.72 18.88 424 59422 184467 90384134
Folliculitis 212.22 18.88 437 59409 203916 90364685
Porphyria acute 200.37 18.88 133 59713 17842 90550759
Fall 200.07 18.88 38 59808 481772 90086829
Impaired healing 190.33 18.88 454 59392 233745 90334856
Muscle injury 180.11 18.88 375 59471 176279 90392322
Duodenal ulcer perforation 179.82 18.88 429 59417 220859 90347742
Grip strength 171.89 18.88 94 59752 8871 90559730
Gastrointestinal disorder 171.47 18.88 462 59384 256225 90312376
Stomatitis 162.44 18.88 473 59373 274225 90294376
Helicobacter infection 160.32 18.88 417 59429 226433 90342168
Irritable bowel syndrome 149.31 18.88 384 59462 207064 90361537
Feeling hot 148.25 18.88 218 59628 77790 90490811
Toxicity to various agents 148.00 18.88 11 59835 287835 90280766
X-ray abnormal 139.68 18.88 161 59685 45263 90523338
Contusion 128.28 18.88 411 59435 250805 90317796
Injury 121.58 18.88 345 59501 197004 90371597
Blister 120.18 18.88 406 59440 254592 90314009
Anti-cyclic citrullinated peptide antibody positive 117.25 18.88 383 59463 236050 90332551
Infusion related reaction 115.86 18.88 563 59283 416217 90152384
Sleep disorder 114.10 18.88 338 59508 197692 90370909
Hand deformity 110.25 18.88 437 59409 295925 90272676
Flushing 109.66 18.88 204 59642 88287 90480314
Swollen joint count 106.16 18.88 68 59778 8585 90560016
Hypersensitivity 106.13 18.88 585 59261 454092 90114509
Lower respiratory tract infection 103.39 18.88 382 59464 250277 90318324
Dislocation of vertebra 102.86 18.88 154 59692 55814 90512787
Road traffic accident 100.98 18.88 221 59625 107405 90461196
Retinitis 99.70 18.88 125 59721 38333 90530268
Discomfort 97.61 18.88 399 59447 273936 90294665
Adjustment disorder with depressed mood 97.01 18.88 151 59695 56602 90511999
Lupus-like syndrome 96.40 18.88 139 59707 48707 90519894
Product dose omission issue 94.78 18.88 37 59809 291650 90276951
Liver disorder 93.99 18.88 231 59615 121038 90447563
Lupus vulgaris 93.01 18.88 131 59715 44928 90523673
Computerised tomogram thorax abnormal 92.76 18.88 39 59807 2048 90566553
Pyrexia 91.91 18.88 747 59099 659738 89908863
Facet joint syndrome 91.13 18.88 201 59645 98188 90470413
Lip dry 90.98 18.88 204 59642 100751 90467850
Glossodynia 88.13 18.88 433 59413 321346 90247255
Autoimmune disorder 85.34 18.88 169 59677 76575 90492026
Colitis ulcerative 84.97 18.88 147 59699 60119 90508482
Hepatic enzyme increased 84.67 18.88 465 59381 360271 90208330
Frequent bowel movements 83.07 18.88 141 59705 56794 90511807
Bone erosion 82.29 18.88 135 59711 52886 90515715
Breast cancer stage III 82.17 18.88 176 59670 84271 90484330
General physical health deterioration 82.17 18.88 456 59390 354659 90213942
Insomnia 81.05 18.88 434 59412 333040 90235561
Pancreatitis 79.13 18.88 155 59691 69671 90498930
Febrile bone marrow aplasia 78.23 18.88 59 59787 9679 90558922
Confusional state 76.48 18.88 476 59370 385729 90182872
Maternal exposure timing unspecified 76.46 18.88 84 59762 22399 90546202
Deep vein thrombosis postoperative 76.42 18.88 154 59692 70655 90497946
C-reactive protein abnormal 74.77 18.88 219 59627 127210 90441391
Pericarditis 72.14 18.88 361 59485 269790 90298811
Wound 72.04 18.88 392 59454 302588 90266013
Joint range of motion decreased 71.97 18.88 225 59621 135418 90433183
Exostosis 71.53 18.88 127 59719 53007 90515594
Infection 71.51 18.88 446 59400 361648 90206953
Lower limb fracture 71.30 18.88 167 59679 84846 90483755
Laryngitis 70.51 18.88 123 59723 50630 90517971
Sciatica 67.08 18.88 182 59664 101200 90467401
Urinary tract infection 65.64 18.88 63 59783 305569 90263032
Swollen joint count increased 62.27 18.88 188 59658 111018 90457583
Overdose 62.12 18.88 14 59832 157695 90410906
Influenza 62.10 18.88 9 59837 139255 90429346
Computerised tomogram thorax 61.45 18.88 20 59826 505 90568096
Systemic lupus erythematosus 61.28 18.88 429 59417 361467 90207134
Weight fluctuation 60.70 18.88 70 59776 19679 90548922
Sinusitis 60.63 18.88 411 59435 342677 90225924
Hepatic cirrhosis 60.58 18.88 131 59715 63122 90505479
Sleep disorder due to a general medical condition 60.30 18.88 107 59739 44631 90523970
Synovitis 59.45 18.88 397 59449 329355 90239246
Neutrophil count decreased 59.42 18.88 140 59706 71392 90497209
Pregnancy 58.85 18.88 128 59718 61919 90506682
Wound infection 57.82 18.88 178 59668 106224 90462377
Rectal haemorrhage 57.21 18.88 151 59695 82593 90486008
Injection site pain 56.45 18.88 22 59824 173677 90394924
Headache 55.70 18.88 338 59508 862408 89706193
Pulmonary fibrosis 53.98 18.88 175 59671 107328 90461273
Mucosal inflammation 53.65 18.88 118 59728 57507 90511094
Rheumatoid factor positive 52.77 18.88 239 59607 171411 90397190
Injection site phlebitis 52.65 18.88 13 59833 114 90568487
Laboratory test abnormal 52.46 18.88 97 59749 41757 90526844
Rheumatic fever 52.26 18.88 220 59626 152901 90415700
White blood cell count increased 51.98 18.88 128 59718 67113 90501488
Delirium 51.60 18.88 169 59677 104190 90464411
Medication error 51.10 18.88 147 59699 84505 90484096
Hepatocellular injury 49.41 18.88 77 59769 28881 90539720
Myocardial infarction 49.27 18.88 6 59840 105966 90462635
Balance disorder 49.04 18.88 4 59842 97076 90471525
Peripheral venous disease 48.04 18.88 143 59703 83778 90484823
C-reactive protein 47.50 18.88 79 59767 31288 90537313
Foot deformity 46.58 18.88 114 59732 59537 90509064
Somnolence 46.16 18.88 42 59804 209042 90359559
Injection site reaction 45.95 18.88 4 59842 92076 90476525
Anaphylactic shock 44.40 18.88 77 59769 31540 90537061
Bronchitis 44.01 18.88 23 59823 152904 90415697
Pain 43.37 18.88 435 59411 995906 89572695
Pruritus 42.97 18.88 546 59300 540979 90027622
Cardiac failure congestive 42.58 18.88 7 59839 98687 90469914
Off label use 41.70 18.88 497 59349 1101755 89466846
Weight increased 41.45 18.88 440 59406 417487 90151114
Amnesia 41.06 18.88 161 59685 108344 90460257
Night sweats 40.85 18.88 181 59665 128585 90440016
Sense of oppression 40.51 18.88 18 59828 1082 90567519
Encephalopathy 39.77 18.88 92 59754 46352 90522249
Blood pressure increased 39.65 18.88 43 59803 197174 90371427
Bursitis 39.48 18.88 182 59664 131472 90437129
Injection site vasculitis 39.42 18.88 7 59839 7 90568594
Stress 39.38 18.88 4 59842 81391 90487210
Aplasia 38.46 18.88 27 59819 3964 90564637
Ear infection 38.15 18.88 117 59729 69658 90498943
Pemphigus 38.14 18.88 356 59490 326508 90242093
Arthropathy 37.91 18.88 389 59457 365853 90202748
Vascular device infection 37.80 18.88 43 59803 11909 90556692
Atelectasis 37.66 18.88 62 59784 24347 90544254
Chronic obstructive pulmonary disease 37.41 18.88 3 59843 73826 90494775
Drug tolerance decreased 37.21 18.88 72 59774 32058 90536543
Colony stimulating factor therapy 37.18 18.88 13 59833 411 90568190
Dyspnoea 37.02 18.88 800 59046 880155 89688446
Walking aid user 36.85 18.88 76 59770 35430 90533171
Infusion site streaking 36.60 18.88 14 59832 573 90568028
Influenza like illness 36.42 18.88 5 59841 80606 90487995
Bone marrow failure 35.86 18.88 71 59775 32150 90536451
Fluid intake reduced 35.23 18.88 26 59820 4126 90564475
Gastrooesophageal reflux disease 34.86 18.88 35 59811 166302 90402299
Nail bed inflammation 34.84 18.88 19 59827 1782 90566819
Renal impairment 34.83 18.88 13 59833 105408 90463193
Suicidal ideation 34.78 18.88 4 59842 73851 90494750
Tonsillar haemorrhage 34.73 18.88 11 59835 254 90568347
Chemotherapy 34.59 18.88 19 59827 1808 90566793
Streptococcal sepsis 33.97 18.88 24 59822 3560 90565041
Lung disorder 33.61 18.88 191 59655 149692 90418909
Dry mouth 33.36 18.88 222 59624 183837 90384764
Grip strength decreased 33.13 18.88 135 59711 92441 90476160
Cellulitis 32.37 18.88 10 59836 91327 90477274
Nasal congestion 31.67 18.88 8 59838 83406 90485195
Nasal mucosal disorder 31.58 18.88 18 59828 1839 90566762
Swelling 30.89 18.88 417 59429 418641 90149960
Cerebrovascular accident 30.77 18.88 22 59824 123511 90445090
Palpitations 30.73 18.88 27 59819 136701 90431900
Rhinorrhoea 30.71 18.88 10 59836 88306 90480295
Erythema 30.50 18.88 257 59589 228989 90339612
Respiratory disorder 30.28 18.88 103 59743 64713 90503888
Pseudomonal sepsis 30.06 18.88 24 59822 4278 90564323
Incorrect dose administered 29.14 18.88 8 59838 78922 90489679
Anti-cyclic citrullinated peptide antibody 27.93 18.88 58 59788 27163 90541438
Blood pressure systolic increased 27.88 18.88 3 59843 58342 90510259
Hypercholesterolaemia 27.71 18.88 136 59710 100756 90467845
COVID-19 27.56 18.88 43 59803 168800 90399801
Diabetes mellitus 27.11 18.88 5 59841 64870 90503731
Cardiac disorder 26.98 18.88 3 59843 56869 90511732
Nasopharyngitis 26.35 18.88 396 59450 406708 90161893
Neck pain 26.22 18.88 22 59824 113941 90454660
Acute kidney injury 25.93 18.88 116 59730 320271 90248330
Unevaluable event 25.76 18.88 3 59843 54845 90513756
Gastrointestinal haemorrhage 25.33 18.88 14 59832 90234 90478367
Haemoglobin decreased 24.80 18.88 43 59803 161913 90406688
Psoriasis 24.72 18.88 37 59809 147717 90420884
Obesity 24.67 18.88 136 59710 105371 90463230
Pneumonia 24.30 18.88 287 59559 637772 89930829
Inflammation 24.16 18.88 201 59645 178391 90390210
Injection site erythema 23.94 18.88 18 59828 98484 90470117
Haemorrhage 23.86 18.88 8 59838 69361 90499240
Dyspnoea exertional 23.73 18.88 9 59837 72279 90496322
Inappropriate schedule of product administration 23.70 18.88 39 59807 149894 90418707
Type 2 diabetes mellitus 23.50 18.88 221 59625 203023 90365578
Herpes zoster 23.38 18.88 17 59829 94627 90473974
Vision blurred 23.34 18.88 23 59823 110270 90458331
Fibromyalgia 23.21 18.88 223 59623 206046 90362555
Lactic acidosis 23.11 18.88 3 59843 50460 90518141
Chronic kidney disease 22.94 18.88 3 59843 50188 90518413
Therapy interrupted 22.89 18.88 3 59843 50105 90518496
Blood creatinine increased 22.80 18.88 20 59826 101366 90467235
Renal failure 22.71 18.88 32 59814 130975 90437626
Heart rate decreased 22.63 18.88 4 59842 53501 90515100
Therapeutic product effect incomplete 22.60 18.88 60 59786 193836 90374765
Abdominal distension 22.54 18.88 32 59814 130569 90438032
Drug interaction 22.42 18.88 100 59746 276353 90292248
Blood glucose increased 22.39 18.88 18 59828 95228 90473373
Depressed level of consciousness 22.38 18.88 10 59836 72774 90495827
Wheezing 22.33 18.88 248 59598 237832 90330769
Musculoskeletal pain 22.25 18.88 191 59655 171060 90397541
Joint dislocation 21.85 18.88 72 59774 44510 90524091
Pain in jaw 21.62 18.88 3 59843 47982 90520619
Abdominal discomfort 21.43 18.88 438 59408 476890 90091711
Dry eye 21.15 18.88 6 59840 57925 90510676
Liver function test abnormal 21.07 18.88 4 59842 50841 90517760
Death 20.75 18.88 197 59649 456354 90112247
Skin ulcer 20.63 18.88 4 59842 50071 90518530
Neutropenic colitis 20.56 18.88 19 59827 4124 90564477
Wrong technique in product usage process 20.24 18.88 11 59835 71560 90497041
Neutropenia 20.06 18.88 232 59614 224672 90343929
Cholelithiasis 20.00 18.88 5 59841 52501 90516100
Cardiac arrest 19.86 18.88 24 59822 104911 90463690
Hyperkalaemia 19.85 18.88 9 59837 64955 90503646
Intentional product misuse 19.76 18.88 18 59828 89586 90479015
Peripheral swelling 19.18 18.88 381 59465 412725 90155876

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 249.39 19.43 301 13312 185402 42422320
Erythema 119.66 19.43 160 13453 108633 42499089
Hiccups 113.72 19.43 62 13551 12109 42595613
Drug ineffective 100.92 19.43 38 13575 630159 41977563
Nausea 95.27 19.43 310 13303 396489 42211233
Neutrophil count decreased 91.63 19.43 107 13506 63308 42544414
Anaphylactic reaction 82.46 19.43 84 13529 42659 42565063
Hypersensitivity 80.34 19.43 107 13506 72263 42535459
Neutropenia 78.65 19.43 187 13426 199244 42408478
Encephalopathy 66.89 19.43 74 13539 41259 42566463
Flushing 61.14 19.43 67 13546 36961 42570761
Stomatitis 59.84 19.43 77 13536 50252 42557470
Vomiting 56.81 19.43 212 13401 289511 42318211
Thrombocytopenia 56.02 19.43 160 13453 190119 42417603
Platelet count decreased 55.68 19.43 131 13482 138450 42469272
Pyrexia 55.17 19.43 260 13353 393782 42213940
White blood cell count decreased 50.62 19.43 110 13503 110286 42497436
Testicular germ cell cancer metastatic 44.51 19.43 9 13604 65 42607657
Hepatocellular injury 42.87 19.43 45 13568 23633 42584089
Interstitial lung disease 42.79 19.43 84 13529 78378 42529344
Procalcitonin decreased 42.63 19.43 11 13602 254 42607468
Decreased appetite 42.61 19.43 147 13466 192990 42414732
Diarrhoea 42.18 19.43 271 13342 460578 42147144
Eosinophil percentage decreased 42.15 19.43 11 13602 266 42607456
Blood creatine decreased 41.99 19.43 11 13602 270 42607452
Febrile bone marrow aplasia 39.94 19.43 30 13583 10151 42597571
Bone marrow failure 38.33 19.43 50 13563 33043 42574679
Hypokalaemia 36.96 19.43 75 13538 71646 42536076
Septic shock 33.92 19.43 84 13529 91588 42516134
Fixed eruption 33.05 19.43 16 13597 2438 42605284
Toxicity to various agents 32.98 19.43 16 13597 229120 42378602
Aplasia 32.75 19.43 20 13593 4823 42602899
Acute kidney injury 31.69 19.43 213 13400 367124 42240598
Seminoma 31.19 19.43 9 13604 319 42607403
Chest discomfort 30.98 19.43 65 13548 63551 42544171
Sense of oppression 30.44 19.43 10 13603 549 42607173
Leukopenia 30.34 19.43 71 13542 74675 42533047
Aortic valve calcification 30.33 19.43 10 13603 555 42607167
Cytokine release syndrome 29.69 19.43 52 13561 44475 42563247
Blood folate decreased 29.61 19.43 11 13602 870 42606852
Condition aggravated 29.55 19.43 24 13589 260730 42346992
Anaphylactic shock 29.54 19.43 37 13576 23480 42584242
Product dose omission issue 28.71 19.43 7 13606 154358 42453364
Infusion related reaction 28.30 19.43 61 13552 60745 42546977
Jaundice 26.52 19.43 43 13570 34546 42573176
Mucosal inflammation 25.86 19.43 52 13561 49322 42558400
Oxygen saturation decreased 25.76 19.43 61 13552 64626 42543096
Rash maculo-papular 25.26 19.43 44 13569 37459 42570263
Anaemia 25.01 19.43 164 13449 280114 42327608
Paraesthesia 24.76 19.43 65 13548 73394 42534328
Constipation 24.73 19.43 110 13503 162181 42445541
Blood urea decreased 24.64 19.43 11 13602 1395 42606327
Platelet count increased 24.28 19.43 23 13590 10680 42597042
Pancytopenia 22.83 19.43 86 13527 117657 42490065
Hypochloraemia 21.97 19.43 9 13604 924 42606798
Necrotising ulcerative gingivostomatitis 20.71 19.43 5 13608 87 42607635
Fall 20.44 19.43 27 13586 234493 42373229
Enteritis 20.37 19.43 21 13592 10795 42596927
Blood magnesium decreased 20.24 19.43 18 13595 7708 42600014
Hyperammonaemic encephalopathy 20.23 19.43 12 13601 2746 42604976
C-reactive protein decreased 19.80 19.43 11 13602 2225 42605497

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 498.98 17.24 763 64575 316004 110207957
Drug ineffective 315.41 17.24 263 65075 1520277 109003684
Sleep disorder due to general medical condition, insomnia type 229.13 17.24 297 65041 105346 110418615
Toxicity to various agents 219.60 17.24 17 65321 480538 110043423
Porphyria acute 216.05 17.24 136 65202 18644 110505317
Fall 195.73 17.24 57 65281 603425 109920536
Grip strength 185.74 17.24 96 65242 9045 110514916
X-ray abnormal 184.29 17.24 164 65174 37953 110486008
Folliculitis 182.54 17.24 343 64995 167310 110356651
Stomatitis 181.82 17.24 455 64883 269787 110254174
Ill-defined disorder 179.67 17.24 328 65010 156525 110367436
Hypersensitivity 177.24 17.24 583 64755 403415 110120546
Muscle injury 161.96 17.24 295 65043 140512 110383449
Impaired healing 160.30 17.24 357 64981 196360 110327601
Duodenal ulcer perforation 159.09 17.24 335 65003 177365 110346596
Feeling hot 156.64 17.24 229 65109 90877 110433084
Flushing 151.52 17.24 243 65095 104493 110419468
Dislocation of vertebra 143.34 17.24 152 65186 43569 110480392
Adjustment disorder with depressed mood 137.59 17.24 149 65189 43734 110480227
Irritable bowel syndrome 137.13 17.24 301 65037 163914 110360047
Helicobacter infection 137.00 17.24 320 65018 181557 110342404
Lupus-like syndrome 135.84 17.24 143 65195 40649 110483312
Retinitis 134.69 17.24 128 65210 32199 110491762
Infusion related reaction 134.36 17.24 512 64826 380650 110143311
Lupus vulgaris 133.32 17.24 130 65208 33753 110490208
Gastrointestinal disorder 126.18 17.24 371 64967 241581 110282380
Autoimmune disorder 121.95 17.24 171 65167 65312 110458649
Hand deformity 119.66 17.24 341 64997 218165 110305796
Road traffic accident 118.42 17.24 221 65117 107177 110416784
Neutrophil count decreased 116.43 17.24 235 65103 120706 110403255
Product dose omission issue 114.61 17.24 25 65313 321757 110202204
Swollen joint count 112.96 17.24 68 65270 8606 110515355
Glossodynia 112.50 17.24 337 65001 221667 110302294
Bone erosion 109.39 17.24 136 65202 46235 110477726
Deep vein thrombosis postoperative 109.17 17.24 154 65184 59137 110464824
Lip dry 109.16 17.24 205 65133 99878 110424083
Facet joint syndrome 108.95 17.24 201 65137 96627 110427334
Swollen joint count increased 106.11 17.24 183 65155 83478 110440483
Breast cancer stage III 104.21 17.24 176 65162 78941 110445020
Anti-cyclic citrullinated peptide antibody positive 102.55 17.24 287 65051 181697 110342264
Liver disorder 101.38 17.24 245 65093 141998 110381963
Joint range of motion decreased 101.32 17.24 223 65115 121609 110402352
Lower limb fracture 101.09 17.24 169 65169 75179 110448782
Laryngitis 101.03 17.24 125 65213 42286 110481675
Rheumatoid factor positive 100.61 17.24 233 65105 131407 110392554
Erythema 100.58 17.24 389 64949 291058 110232903
Febrile bone marrow aplasia 98.33 17.24 82 65256 17383 110506578
Exostosis 97.71 17.24 128 65210 45828 110478133
Pyrexia 97.19 17.24 881 64457 897384 109626577
Sciatica 91.87 17.24 182 65156 92217 110431744
Blister 90.62 17.24 318 65020 227058 110296903
Rheumatic fever 90.44 17.24 214 65124 122365 110401596
Computerised tomogram thorax abnormal 89.15 17.24 40 65298 2755 110521206
C-reactive protein abnormal 88.82 17.24 220 65118 129475 110394486
Discomfort 88.79 17.24 304 65034 214403 110309558
Maternal exposure timing unspecified 85.25 17.24 82 65256 20931 110503030
Pregnancy 84.35 17.24 126 65212 50941 110473020
Wound 83.39 17.24 316 65022 234121 110289840
Wound infection 82.97 17.24 179 65159 96286 110427675
Systemic lupus erythematosus 81.70 17.24 332 65006 254006 110269955
Contusion 80.91 17.24 312 65026 233049 110290912
Hepatic enzyme increased 80.48 17.24 389 64949 320503 110203458
Sleep disorder 78.43 17.24 277 65061 198367 110325594
Injury 75.93 17.24 254 65084 177011 110346950
Frequent bowel movements 75.08 17.24 144 65194 71246 110452715
Encephalopathy 75.03 17.24 155 65183 80900 110443061
Pulmonary fibrosis 74.02 17.24 177 65161 101865 110422096
Overdose 74.00 17.24 23 65315 233771 110290190
Hepatocellular injury 73.89 17.24 118 65220 50524 110473437
Foot deformity 73.55 17.24 115 65223 48365 110475596
Hiccups 71.57 17.24 60 65278 12809 110511152
Pancreatitis 70.84 17.24 165 65173 93368 110430593
Colitis ulcerative 70.51 17.24 147 65191 77216 110446745
Hepatic cirrhosis 69.39 17.24 135 65203 67491 110456470
Lower respiratory tract infection 67.76 17.24 304 65034 242802 110281159
Weight fluctuation 67.33 17.24 74 65264 22071 110501890
Sense of oppression 67.03 17.24 28 65310 1620 110522341
Aplasia 64.07 17.24 46 65292 7827 110516134
Computerised tomogram thorax 63.60 17.24 20 65318 506 110523455
Pemphigus 61.82 17.24 271 65067 214299 110309662
Sleep disorder due to a general medical condition 60.90 17.24 110 65228 52002 110471959
Peripheral venous disease 60.03 17.24 145 65193 83972 110439989
Laboratory test abnormal 59.29 17.24 99 65239 43980 110479981
Myocardial infarction 58.83 17.24 20 65318 192063 110331898
Cardiac failure congestive 57.38 17.24 10 65328 150990 110372971
Pericarditis 57.34 17.24 269 65069 218845 110305116
Urinary tract infection 57.24 17.24 65 65273 326217 110197744
Anaphylactic shock 56.70 17.24 106 65232 51440 110472521
Insomnia 56.69 17.24 386 64952 360204 110163757
Walking aid user 56.68 17.24 72 65266 25003 110498958
C-reactive protein 56.15 17.24 79 65259 30252 110493709
Synovitis 56.04 17.24 314 65024 273778 110250183
Ear infection 55.77 17.24 118 65220 62614 110461347
Amnesia 55.23 17.24 162 65176 105246 110418715
Bone marrow failure 53.98 17.24 111 65227 57737 110466224
Night sweats 53.87 17.24 188 65150 133795 110390166
Sinusitis 53.62 17.24 329 65009 296359 110227602
Infection 53.57 17.24 382 64956 361818 110162143
Balance disorder 53.51 17.24 4 65334 116556 110407405
Bursitis 52.84 17.24 183 65155 129735 110394226
White blood cell count increased 51.85 17.24 150 65188 96692 110427269
Grip strength decreased 51.73 17.24 133 65205 80041 110443920
Drug tolerance decreased 51.38 17.24 72 65266 27468 110496493
Somnolence 48.21 17.24 63 65275 297386 110226575
Death 47.99 17.24 231 65107 698638 109825323
Delirium 47.97 17.24 182 65156 134843 110389118
Fibromyalgia 47.81 17.24 214 65124 170695 110353266
Injection site pain 47.22 17.24 23 65315 177899 110346062
Rectal haemorrhage 47.18 17.24 167 65171 119666 110404295
Mucosal inflammation 46.82 17.24 144 65194 95997 110427964
Neutropenia 45.84 17.24 378 64960 374242 110149719
Type 2 diabetes mellitus 45.21 17.24 216 65122 177016 110346945
Influenza 44.66 17.24 22 65316 169079 110354882
Anti-cyclic citrullinated peptide antibody 44.61 17.24 57 65281 19907 110504054
Colony stimulating factor therapy 44.25 17.24 16 65322 626 110523335
Lung disorder 44.17 17.24 217 65121 179830 110344131
Hypercholesterolaemia 43.25 17.24 135 65203 90702 110433259
Blood pressure increased 42.61 17.24 54 65284 258319 110265642
Decreased appetite 42.10 17.24 448 64890 475398 110048563
General physical health deterioration 41.72 17.24 409 64929 424886 110099075
Cerebrovascular accident 41.59 17.24 28 65310 181256 110342705
Neutropenic colitis 41.57 17.24 36 65302 8029 110515932
Injection site reaction 41.05 17.24 3 65335 89067 110434894
Joint dislocation 41.01 17.24 73 65265 34117 110489844
Suicidal ideation 41 17.24 4 65334 93933 110430028
Dry mouth 40.81 17.24 229 65109 199719 110324242
COVID-19 40.64 17.24 51 65287 245009 110278952
Cognitive disorder 40.18 17.24 3 65335 87508 110436453
Chronic obstructive pulmonary disease 39.82 17.24 8 65330 109150 110414811
Pain 39.67 17.24 367 64971 954588 109569373
Rhabdomyolysis 39.63 17.24 11 65327 120390 110403571
Testicular germ cell cancer metastatic 39.11 17.24 9 65329 64 110523897
Intentional product misuse 38.72 17.24 15 65323 132889 110391072
Respiratory disorder 38.63 17.24 111 65227 71271 110452690
Haemorrhage 38.55 17.24 8 65330 106684 110417277
Vomiting 38.50 17.24 753 64585 909922 109614039
Infusion site streaking 38.05 17.24 14 65324 576 110523385
Thrombocytopenia 37.94 17.24 343 64995 348542 110175419
Nail bed inflammation 37.48 17.24 20 65318 2010 110521951
Injection site vasculitis 37.36 17.24 7 65331 14 110523947
Vascular device infection 36.67 17.24 47 65291 16465 110507496
Chemotherapy 36.44 17.24 20 65318 2126 110521835
Nasal congestion 36.28 17.24 7 65331 98275 110425686
Arthropathy 36.17 17.24 292 65046 287230 110236731
Nasal mucosal disorder 36.03 17.24 19 65319 1864 110522097
Pruritus 36.03 17.24 512 64826 581048 109942913
Swelling 35.60 17.24 340 64998 350701 110173260
Cellulitis 35.45 17.24 15 65323 126001 110397960
Pulmonary oedema 35.44 17.24 8 65330 100651 110423310
Headache 34.98 17.24 343 64995 882034 109641927
Paraesthesia 34.87 17.24 281 65057 276240 110247721
Illness 34.58 17.24 4 65334 82167 110441794
Medication error 34.15 17.24 138 65200 105228 110418733
Abdominal distension 33.94 17.24 32 65306 175071 110348890
Anaphylactic reaction 33.38 17.24 145 65193 114155 110409806
Influenza like illness 33.27 17.24 6 65332 88406 110435555
Incorrect dose administered 33.13 17.24 10 65328 103631 110420330
Nausea 33.05 17.24 959 64379 1234731 109289230
Blood pressure systolic increased 32.63 17.24 5 65333 82986 110440975
Heart rate decreased 32.51 17.24 5 65333 82751 110441210
Inflammation 32.22 17.24 210 65128 193028 110330933
Off label use 31.83 17.24 661 64677 1499524 109024437
Chronic kidney disease 31.40 17.24 4 65334 76287 110447674
Atelectasis 29.15 17.24 66 65272 36646 110487315
Drug interaction 28.94 17.24 175 65163 500008 110023953
Streptococcal sepsis 28.93 17.24 24 65314 5048 110518913
Obesity 28.78 17.24 138 65200 113213 110410748
Wrong technique in product usage process 28.71 17.24 8 65330 87340 110436621
Prescribed overdose 28.62 17.24 115 65223 87466 110436495
Nephrolithiasis 28.43 17.24 3 65335 66209 110457752
Gastrooesophageal reflux disease 28.25 17.24 39 65299 179937 110344024
Haemoglobin decreased 28.17 17.24 66 65272 248661 110275300
Osteoporosis 28.13 17.24 114 65224 87038 110436923
Gastrointestinal haemorrhage 27.90 17.24 34 65304 165484 110358477
Bronchitis 27.82 17.24 31 65307 157001 110366960
Wheezing 27.77 17.24 251 65087 254979 110268982
Drug ineffective for unapproved indication 27.73 17.24 13 65325 102825 110421136
Injection site phlebitis 27.60 17.24 8 65330 152 110523809
Blood glucose increased 27.13 17.24 23 65315 132473 110391488
Hallucination 27.08 17.24 13 65325 101419 110422542
Enteritis 27.07 17.24 44 65294 19112 110504849
Seminoma 26.70 17.24 9 65329 285 110523676
Urticaria 26.68 17.24 297 65041 318560 110205401
Palpitations 26.53 17.24 33 65305 159179 110364782
Therapeutic product effect incomplete 26.47 17.24 58 65280 223747 110300214
Alopecia 26.22 17.24 330 65008 364423 110159538
Disturbance in attention 26.13 17.24 3 65335 61992 110461969
Injection site swelling 26.02 17.24 3 65335 61787 110462174
Confusional state 26.02 17.24 405 64933 468275 110055686
Fluid intake reduced 25.98 17.24 26 65312 6960 110517001
Musculoskeletal pain 25.85 17.24 191 65147 182832 110341129
Cardiac arrest 25.83 17.24 48 65290 196705 110327256
Dyspnoea 25.55 17.24 844 64494 1106028 109417933
Dyspnoea exertional 25.34 17.24 15 65323 104045 110419916
Live birth 24.95 17.24 94 65244 69390 110454571
Cataract 24.81 17.24 8 65330 79477 110444484
Inappropriate schedule of product administration 24.73 17.24 52 65286 203585 110320376
Cardiac failure 24.43 17.24 46 65292 187580 110336381
Palmar-plantar erythrodysaesthesia syndrome 24.37 17.24 66 65272 40959 110483002
Weight increased 24.20 17.24 365 64973 419279 110104682
Agitation 23.92 17.24 19 65319 113032 110410929
Rash maculo-papular 23.88 17.24 97 65241 74125 110449836
Hypokalaemia 23.31 17.24 186 65152 182262 110341699
Renal impairment 22.98 17.24 48 65290 188397 110335564
Respiratory failure 22.92 17.24 59 65279 215273 110308688
Transposition of the great vessels 22.89 17.24 6 65332 77 110523884
Myalgia 22.86 17.24 62 65276 222319 110301642
Hyperkalaemia 22.78 17.24 28 65310 135768 110388193
Tonsillar haemorrhage 22.71 17.24 8 65330 290 110523671
Joint stiffness 22.53 17.24 89 65249 67154 110456807
Paronychia 22.22 17.24 30 65308 11051 110512910
Cytomegalovirus infection 22.06 17.24 3 65335 54441 110469520
Rhinorrhoea 22.05 17.24 17 65321 102649 110421312
Diabetes mellitus 21.93 17.24 16 65322 99365 110424596
Orthostatic hypotension 21.90 17.24 6 65332 66243 110457718
International normalised ratio increased 21.85 17.24 12 65326 86760 110437201
Interstitial lung disease 21.76 17.24 149 65189 139185 110384776
Multiple organ dysfunction syndrome 21.74 17.24 35 65303 151675 110372286
Psoriatic arthropathy 21.65 17.24 194 65144 196567 110327394
Liver function test abnormal 21.42 17.24 7 65331 68943 110455018
Viral infection 21.36 17.24 3 65335 53136 110470825
Oedema 21.08 17.24 203 65135 209773 110314188
Blood pressure fluctuation 20.89 17.24 9 65329 74815 110449146
Dental fistula 20.55 17.24 9 65329 585 110523376
Visual impairment 20.55 17.24 143 65195 134285 110389676
Condition aggravated 20.54 17.24 308 65030 734528 109789433
Cholelithiasis 20.49 17.24 6 65332 63416 110460545
Bradycardia 20.35 17.24 38 65300 155479 110368482
Pulmonary hypertension 20.24 17.24 4 65334 55216 110468745
Psychotic disorder 20.18 17.24 3 65335 50934 110473027
Platelet count decreased 19.89 17.24 216 65122 230227 110293734
Accidental exposure to product 19.69 17.24 3 65335 50005 110473956
Hip arthroplasty 19.62 17.24 75 65263 55738 110468223
Blood creatinine increased 19.55 17.24 50 65288 182839 110341122
Mobility decreased 19.33 17.24 220 65118 237202 110286759
White blood cell count decreased 19.33 17.24 214 65124 229176 110294785
Prescribed underdose 19.27 17.24 83 65255 65091 110458870
Depressed mood 19.20 17.24 6 65332 60803 110463158
Renal failure 19.17 17.24 69 65269 226505 110297456
Liver injury 19.02 17.24 153 65185 150260 110373701
Drug resistance 18.83 17.24 5 65333 56369 110467592
Adverse event 18.59 17.24 119 65219 108690 110415271
Herpes zoster 18.54 17.24 22 65316 108357 110415604
Plasma cell myeloma 18.50 17.24 7 65331 62929 110461032
Sedation 18.49 17.24 9 65329 69674 110454287
Unevaluable event 18.42 17.24 6 65332 59221 110464740
Pain in jaw 18.15 17.24 4 65334 51173 110472788
Acute myocardial infarction 17.83 17.24 14 65324 83763 110440198
Psoriasis 17.63 17.24 35 65303 139958 110384003
Varicose vein 17.41 17.24 21 65317 6919 110517042
Pseudomonal sepsis 17.40 17.24 24 65314 9022 110514939
Lymphadenopathy 17.32 17.24 8 65330 63827 110460134

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA MoA N0000010262 Neurokinin 1 Antagonists
MeSH PA D000932 Antiemetics
MeSH PA D002491 Central Nervous System Agents
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D064729 Neurokinin-1 Receptor Antagonists
FDA EPC N0000175786 Substance P/Neurokinin-1 Receptor Antagonist
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:50266 prodrug
CHEBI has role CHEBI:50919 antiemetic
CHEBI has role CHEBI:55350 neurokinin-1 receptor antagonist
CHEBI has role CHEBI:63726 neuroprotective agent

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chemotherapy-induced nausea and vomiting indication 236084000
Hepatic failure contraindication 59927004




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 0.87 acidic
pKa2 6.2 acidic
pKa3 8.25 acidic
pKa4 10.36 acidic
pKa5 3.99 Basic
pKa6 1.47 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Substance-P receptor GPCR ANTAGONIST IC50 8.92 IUPHAR CHEMBL

External reference:

IDSource
D06597 KEGG_DRUG
4027247 VUID
N0000176136 NUI
265121-04-8 SECONDARY_CAS_RN
4027246 VANDF
4027247 VANDF
CHEBI:64321 CHEBI
CHEMBL1199324 ChEMBL_ID
CHEMBL1201782 ChEMBL_ID
C579707 MESH_SUPPLEMENTAL_RECORD_UI
7623 IUPHAR_LIGAND_ID
8699 INN_ID
DB06717 DRUGBANK_ID
6L8OF9XRDC UNII
1731071 RXNORM
25045 MMSL
322336 MMSL
d07080 MMSL
012534 NDDF
012535 NDDF
429822007 SNOMEDCT_US
429825009 SNOMEDCT_US
434337009 SNOMEDCT_US
C2349941 UMLSCUI
135413538 PUBCHEM_CID
6L8OF9XRDC INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
EMEND HUMAN PRESCRIPTION DRUG LABEL 1 0006-3061 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS NDA 29 sections
EMEND HUMAN PRESCRIPTION DRUG LABEL 1 0006-3061 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS NDA 29 sections
EMEND HUMAN PRESCRIPTION DRUG LABEL 1 0006-3884 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 115 mg INTRAVENOUS NDA 29 sections
EMEND HUMAN PRESCRIPTION DRUG LABEL 1 0006-3941 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS NDA 29 sections
FOSAPREPITANT DIMEGLUMINE HUMAN PRESCRIPTION DRUG LABEL 1 0143-9384 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 29 sections
FOSAPREPITANT DIMEGLUMINE HUMAN PRESCRIPTION DRUG LABEL 1 0143-9428 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 29 sections
Fosaprepitant HUMAN PRESCRIPTION DRUG LABEL 1 0338-0008 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 28 sections
Fosaprepitant HUMAN PRESCRIPTION DRUG LABEL 1 0591-4385 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS NDA 27 sections
Fosaprepitant HUMAN PRESCRIPTION DRUG LABEL 1 16714-248 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 26 sections
Fosaprepitant HUMAN PRESCRIPTION DRUG LABEL 1 31722-165 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 27 sections
Fosaprepitant HUMAN PRESCRIPTION DRUG LABEL 1 43598-671 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 26 sections
Fosaprepitant HUMAN PRESCRIPTION DRUG LABEL 1 43598-859 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 28 sections
Fosaprepitant HUMAN PRESCRIPTION DRUG LABEL 1 43598-948 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 28 sections
FOSAPREPITANT DIMEGLUMINE Human Prescription Drug Label 1 55150-299 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 27 sections
Fosaprepitant HUMAN PRESCRIPTION DRUG LABEL 1 63323-972 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 29 sections
FOSAPREPITANT DIMEGLUMINE HUMAN PRESCRIPTION DRUG LABEL 1 67184-0540 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 29 sections
fosaprepitant HUMAN PRESCRIPTION DRUG LABEL 1 67457-889 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 30 sections
Fosaprepitant HUMAN PRESCRIPTION DRUG LABEL 1 68001-421 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 27 sections
Fosaprepitant HUMAN PRESCRIPTION DRUG LABEL 1 68001-523 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 26 sections
Fosaprepitant HUMAN PRESCRIPTION DRUG LABEL 1 68001-675 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 24 sections
fosaprepitant Human Prescription Drug Label 1 69097-830 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 26 sections
FOCINVEZ HUMAN PRESCRIPTION DRUG LABEL 1 70121-2631 INJECTION 150 mg INTRAVENOUS NDA 27 sections
FOSAPREPITANT HUMAN PRESCRIPTION DRUG LABEL 1 71731-5111 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 28 sections
fosaprepitant Human Prescription Drug Label 1 71839-104 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 26 sections
fosaprepitant Human Prescription Drug Label 1 71839-104 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 26 sections
Fosaprepitant HUMAN PRESCRIPTION DRUG LABEL 1 72162-2636 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 24 sections
Fosaprepitant Human Prescription Drug Label 1 72205-054 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 24 sections
Fosaprepitant Human Prescription Drug Label 1 72205-083 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 24 sections
Fosaprepitant Human Prescription Drug Label 1 72603-450 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 24 sections
FOSAPREPITANT HUMAN PRESCRIPTION DRUG LABEL 1 81952-911 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 150 mg INTRAVENOUS ANDA 28 sections